Vitamin D plasma level can affect nivolumab drug exposure in a cohort of patients with non-small-cell lung cancer

AUTORI

Jessica Cusato¹, Carlo Genova², Cristina Tomasello³, Paolo Carrega^4,5, Selene Ottonello^6,7, Gabriella Pietra^6,8, Maria Cristina Mingari^6,7,8, Irene Cossu⁹, Erika Rijavec¹⁰, Anna Leggieri³, Giovanni Di Perri¹, Maria Giovanna Dal Bello¹⁰, Simona Coco¹⁰, Simona Boccardo¹⁰, Guido Ferlazzo^4,5,11, Francesco Grossi^2* and Antonio D’Avolio^1,12
¹Department of Medical Sciences, University of Torino, Amedeo di Savoia Hospital, Torino
²Medical Oncology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano
³Hospital Pharmacy- M.Vittoria Hospital - ASL Città di Torino, Torino
⁴Laboratory of Immunology and Biotherapy, Department of Human Pathology, University of Messina
⁵Cell Factory Center, University of Messina
⁶Department of Experimental Medicine (DiMES), University of Genova
⁷Center of Excellence for Biomedical Research (CEBR), University of Genova
⁸Immunology Unit, IRCCS Ospedale Policlinico San Martino, Genova
⁹Giannina Gaslini Institute, Genova
¹⁰Lung Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genova
¹¹Division of Clinical Pathology, University Hospital Policlinico G. Martino, Messina
¹²Interdepartmental Center for Clinical and Experimental Pharmacology (CIFACS), University of Torino

ABSTRACT

Introduction: immune-checkpoint inhibition using programmed cell death-1 and its ligand drug inhibitors have improved survival, among patients with advanced non-small-cell lung cancer (NSCLC): nivolumab is one of the last approved. Vitamin D deficiency (<20 ng/mL) is frequent in lung cancer patients and studies showed this pre-hormone modulates the expression of genes involved in drug pathway and in the immune system regulation. Furthermore, not many biomarkers related to nivolumab therapy are present in literature. The aim of this study was to understand which factors were able to predict nivolumab concentrations and its anti-antibody levels in patients’ plasma at 15, 45 and 60 days of therapy.
Methods: forty-five patients with advanced NSCLC were enrolled to receive nivolumab. Enzyme-linked immunosorbent assay was used for drug and vitamin D quantification.
Results: Median nivolumab plasma levels were 12.5, 22.3 and 27.1 μg/mL respectively at 15, 45 and 60 days (p<0.001). No anti-nivolumab antibodies have been detected. 25-hydroxyvitamin D median concentrations were 12.8 ng/mL at baseline, 13.6 ng/mL at 15 days, 11.8 ng/mL at 45 days and 12.9 ng/mL at 60 days. Gender significantly affected nivolumab concentrations (p=0.010 at 15 days, p=0.033 at 45 days and p=0.006 at 60 days). In linear regression analyses, 25-hydroxyvitamin D <20 ng/mL before starting therapy, gender and 25-hydroxyvitamin D <20 ng/mL at 15 days were able to predict nivolumab concentrations respectively at 15, 45 and 60 days of treatment.
Conclusions: for the first time, this study shows factors able to predict nivolumab exposure at different timings, but further, studies in bigger and different cohorts are needed to clarify these data.

BIBLIOGRAFIA

1. F.a.D.A. (FDA). FDA grants nivolumab accelerated approval for third-line treatment of metastatic small cell lung cancer. 2015.https://www.fda.gov/Drugs/
InformationOnDrugs/ApprovedDrugs/ucm617370.htm. (ultimo accesso: aprile 2019).
2. S. Bristol-Meyers. OpdivoR_safety data sheet. 2018;7.2.
3. Tykodi SS, Schadendorf D, Cella D et al. Patient-reported outcomes with nivolumab in advanced solid cancers. Cancer Treat Rev 2018;70:75-87.
4. Bajaj G, Wang X, Agrawal S et al. Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors. CPT Pharmacometrics Syst Pharmacol 2016;6:58-66.
5. Bersanelli M, Leonetti A, Buti S. The link between calcitriol and anticancer immunotherapy: vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockade. Immunotherapy 2017; 9:1127-31.
6. Hoffer LJ, Robitaille L, Swinton N et al. Appropriate vitamin D loading regimen for patients with advanced lung cancer. Nutr J 2016;15:84.
7. Akiba T, Morikawa T, Odaka M et al. Vitamin D Supplementation and survival of patients with non-small cell lung cancer: A randomized, double-blind, placebo-controlled trial. clin cancer res 2018;24:4089-97.
8. Cusato J, Genova C, Tomasello C et al. Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Cancers (Basel 2019. doi:10.3390/cancers11010125.
9. Feng Y, Wang X, Bajaj G et al. Nivolumab exposure-response analyses of efficacy and safety in previously treated squamous or nonsquamous non-small cell lung cancer. Clin Cancer Res 2017;23:5394-405.
10. Agnello L, Scazzone C, Lo Sasso B et al. VDBP, CYP27B1, and 25-Hydroxyvitamin D gene polymorphism analyses in a group of sicilian multiple sclerosis patients. Biochem Genet 2016;55:183-92.
11. Schuster I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta 2010;1814:186-99.